NCT03075527 2026-01-08
A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma
Dana-Farber Cancer Institute
Phase 2 Terminated
Clinical Trials
4 trialsNCT04613492 2025-06-24
A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors
AstraZeneca
Phase 1 Terminated
NCT03665129 2022-01-27
STELLAR-001
Innate Pharma
Phase 1 Terminated
NCT02737072 2019-08-12
A Study of LY2510924 and Durvalumab in Participants With Solid Tumors
Eli Lilly and Company
Phase 1 Terminated